Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Kobayashi Pharmaceutical Co., Ltd.    4967   JP3301100008

KOBAYASHI PHARMACEUTICAL CO., LTD.

(4967)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Kobayashi Pharmaceutical : FY2017 1Q Financial Statement

share with twitter share with LinkedIn share with facebook
08/09/2016 | 09:07pm EDT
Summary of Financial Statements (Japanese GAAP) (Consolidated) Financial Results for the 1st Quarter of the Fiscal Year Ending December 31, 2016

July 28, 2016

Listed exchanges : Tokyo

Listed company name: Kobayashi Pharmaceutical Co., Ltd. Code : 4967

URL : http://www.kobayashi.co.jp/ Representative officer: Akihiro Kobayashi, President & COO Contact : Satoshi Yamane,

Senior Executive Director & Senior General Manager, Corporate Administration Headquarters

Tel : +81-6-6222-0142

Expected date for submitting quarterly securities report : August 9, 2016 Preparation of supplementary explanation documents for quarterly financial results : None

Holding of an analyst meeting for quarterly financial results : None

(Any fraction less than 1 million yen is rounded down to the nearest million yen.)

1. Consolidated Results for 1st Quarter of Fiscal Year Ending December 31, 2016 (April 1, 2016 to June 30, 2016)

(1) Consolidated Operating Results (accumulation)

(% figures represent changes from same period in previous year)

Q1 of FY ending December 31, 2016 Q1 of FY ended March 31, 2016

Net sales

36,767

millions of yen

%

29,971

millions of yen

10.3

%

Operating income

7,299

4,453

33.8

Ordinary income

7,142

4,632

28.6

Net income attributable to owners of the parent

5,219

2,884

19.3

Net income per share

64.97

yen

35.43

yen

Net income per share after full dilution

64.92

(Note) Comprehensive income: Q1 of FY ending December 31, 2016: 1,243 million yen (%)

Q1 of FY ended March 31, 2016 : 4,874 million yen (192.6%)

  1. Following the approval of the proposal "Partial Amendment to the Articles of Incorporation" at the 98th Ordinary General Meeting of Shareholders held on June 29, 2016, the Company changed the book-closing date from March 31 to December 31, effective from FY 2016. Accordingly, the current consolidated fiscal year is a transitional period for the change in accounting period, meaning an irregular period, in which the consolidated operating results cover three months (April 1, 2016 to June 30, 2016) for the Company and its consolidated subsidiaries that close their accounts in March, as opposed to six months (January 1, 2016 to June 30, 2016) for consolidated subsidiaries that close their accounts in December. Therefore, the percentage of year-on-year changes has been omitted in the tables above.

  2. The Company implemented a two-for-one common stock split effective July 1, 2016. Net income per share and net income per share after full dilution were calculated on the assumption that the relevant stock split had been implemented at the beginning of the previous consolidated fiscal year.

(2) Consolidated Financial Position

Q1 of FY ending December 31, 2016

As of March 31, 2016

Total assets

188,754

millions of yen

188,997

millions of yen

Net assets

141,378

142,023

Shareholders' equity ratio

74.8

%

75.1

%

Net assets per share

1,758.24

yen

1,766.06

yen

(Reference) Shareholders' equity

Q1 of FY ending December 31, 2016: 141,257 million yen As of March 31, 2016: 141,873 million yen

The Company implemented a two-for-one common stock split effective July 1, 2016. Net assets per share were calculated on the assumption that the relevant stock split had been implemented at the beginning of the previous consolidated fiscal year.

2. Dividends

Year ended March 2016

FY ending December 2016

FY ending December 2016 (forecasts)

Dividends per share

Q1 end

Q2 end

48.00

yen

24.00

yen

Q3 end

Year-end

48.00

24.00

Total

96.00

48.00

(Note) Revision of the latest dividend forecast: None

The Company implemented a two-for-one common stock split effective July 1, 2016. The Q2-end and year-end dividends per share for the consolidated fiscal year ending December 31, 2016 (forecast) are stated taking into consideration the relevant stock split.

3. Forecasts of Consolidated Operational Results for Fiscal Year Ending December 31, 2016 (April 1, 2016 to December 31, 2016)

(% figures represent changes from same period in previous year) 6-month period ending September 30, 2016

(accumulation) FY ending December 31, 2016

Net sales

73,000

millions of yen

%

117,300

millions of yen

%

Operating income

10,600

16,900

Ordinary income

10,600

18,800

Net income attributable to

7,000

13,500

owners of the parent

Earnings per share

87.13

yen

168.04

yen

(Note) Revision of the latest forecasts of operational results: Yes

  1. Following the approval of the proposal "Partial Amendment to the Articles of Incorporation" at the 98th Ordinary General Meeting of Shareholders held on June 29, 2016, the Company changed the book-closing date from March 31 to December 31, effective from FY 2016. Accordingly, the consolidated fiscal year ending December 31, 2016 is a transitional period for the change in accounting period, covering nine months (April 1, 2016 to December 31, 2016) for the Company and its consolidated subsidiaries that close their accounts in March. The consolidated accounting period for the consolidated subsidiaries that close their accounts in December covers 12 months (January 1, 2016 to December 31, 2016) as in the previous year.

    [Reference]

    Net sales

    Operating income

    Ordinary income

    Net income attributable to owners of the parent

    (Millions of yen)

    117,300

    4.3%

    16,900

    (1.9%)

    18,800

    10.0%

    13,500

    5.8%

    The percentages shown below (adjusted changes) represent ratios of change by comparing the nine-month results for the previous fiscal year for the Company and its consolidated subsidiaries that close their accounts in March (April 1, 2015 to December 31, 2015) and 12-month results for the previous fiscal year for the consolidated subsidiaries that close their accounts in December (January 1, 2015 to December 31, 2015) with the full-year forecasts for the fiscal year ending December 31, 2016.

  2. The Company implemented a two-for-one common stock split effective July 1, 2016. Net income per share for the first six-month period and the full-year for the consolidated fiscal year ending December 31, 2016 is stated taking into consideration the relevant stock split.

* Notes

  1. Changes in significant subsidiaries during the period (Changes in specified subsidiaries accompanying changes of the scope of consolidation): None

    Newly consolidated: - (company name: ), Eliminated from the scope of consolidation: - (company name: )

  2. Adoption of special accounting methods for preparing quarterly consolidated financial statements: None

  3. Changes in accounting policies, changes in accounting estimates and retrospective restatement

    Changes in accounting policies due to revisions of accounting standards: None

    Changes of accounting policies other than the above: None

    Changes in accounting estimates: None

    Retrospective restatement: None

    Q1 of FY ending December 31, 2016

    85,050,000

    shares

    FY ended March 31, 2016

    85,050,000

    shares

    Q1 of FY ending December 31, 2016

    4,709,426

    shares

    FY ended March 31, 2016

    4,716,626

    shares

    Q1 of FY ending December 31, 2016

    80,335,996

    shares

    Q1 of FY ended March 31, 2016

    81,434,432

    shares

  4. Issued shares (common shares)

Number of shares issued at period-end (including treasury stock):

Number of shares of treasury stock at period-end

Average number of shares outstanding during period (consolidated cumulative quarters)

The Company implemented a two-for-one common stock split effective July 1, 2016. Number of issued shares (common shares) was calculated on the assumption that the relevant stock split had been implemented at the beginning of the previous consolidated fiscal year.

  • Information on implementation of quarterly review procedures

    This brief report of quarterly financial statements is not subject to audit procedures under the Financial Instruments and Exchange Act. Audit procedures concerning quarterly financial statements have not been completed under the Financial Instruments and Exchange Act at the date of disclosure of this brief report of quarterly financial statements.

  • Explanation on appropriate use of forecasts of business results and other special items

The forward-looking statements in this document concerning forecasting of operational results, etc. are based on currently available information and assumptions considered reasonable by the Company. Actual operational results may be significantly different from these statements due to various factors. For the assumptions used as the basis for forecasts of operational results and important matters when using the forecast of performance, please refer to "1. Qualitative Information on Quarterly Results, (3) Explanation of future forecast information, such as forecast of consolidated results" on page 4 of the attachment.

Kobayashi Pharmaceutical Co., Ltd. (4967)

Summary of Financial Statements 1st Quarter of the Fiscal Year Ending December 31, 2016

Table of Contents for Attachment

  1. Qualitative Information on Quarterly Results 2

  2. Explanation of operational results 2

  3. Explanation of financial position 3

  4. Explanation of future forecast information, such as forecast of consolidated results 4

  5. Matters concerning Summary Information (Notes) 4

  6. Changes in significant subsidiaries during the period 4

  7. Adoption of special accounting methods for preparing quarterly consolidated financial statements 4

  8. Changes in accounting policies 4

  9. Additional information 4

  10. Quarterly Financial Statements 5

  11. Consolidated quarterly balance sheet 5

  12. Consolidated quarterly statements of income and consolidated quarterly statements of comprehensive income 7

    Consolidated quarterly statements of income

    Three-month period ended June 30, 2016 7

    Consolidated quarterly statements of comprehensive income

    Three-month period ended June 30, 2016 8

  13. Notes on quarterly consolidated financial statements 9

  14. (Notes on assumption of going concern) 9

    (Notes on a significant change in shareholders' equity) 9

    (Segment information, etc.) 9

    (Significant subsequent events) 10

    - 1 -

Kobayashi Pharmaceutical Co. Ltd. published this content on 28 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 August 2016 01:07:10 UTC.


share with twitter share with LinkedIn share with facebook
All news about KOBAYASHI PHARMACEUTICAL CO., LTD.
06/29KOBAYASHI PHARMACEUTICAL CO., LTD. : Ex-dividend day for interim dividend
FA
2019KOBAYASHI PHARMACEUTICAL CO LTD : Ex-dividend day for final dividend
FA
2019KOBAYASHI PHARMACEUTICAL CO LTD : Ex-dividend day for interim dividend
FA
2018KOBAYASHI PHARMACEUTICAL CO LTD : Ex-dividend day for final dividend
FA
2018KOBAYASHI PHARMACEUTICAL CO LTD : quaterly earnings release
2018KOBAYASHI PHARMACEUTICAL CO LTD : Ex-dividend day for interim dividend
FA
2017KOBAYASHI PHARMACEUTICAL CO LTD : Ex-dividend day for final dividend
FA
2017KOBAYASHI PHARMACEUTICAL CO LTD : Ex-dividend day for interim dividend
FA
2017KOBAYASHI PHARMACEUTICAL : Notice Concerning Proxy Voting Policy in The Kobayash..
PU
2016KOBAYASHI PHARMACEUTICAL CO LTD : Ex-dividend day for final dividend
FA
More news
Financials
Sales 2020 157 B 1 485 M 1 485 M
Net income 2020 19 386 M 184 M 184 M
Net cash 2020 93 309 M 884 M 884 M
P/E ratio 2020 41,8x
Yield 2020 0,73%
Capitalization 809 B 7 671 M 7 662 M
EV / Sales 2020 4,57x
EV / Sales 2021 4,29x
Nbr of Employees 3 435
Free-Float 62,2%
Chart KOBAYASHI PHARMACEUTICAL CO., LTD.
Duration : Period :
Kobayashi Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KOBAYASHI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 9 075,71 JPY
Last Close Price 10 350,00 JPY
Spread / Highest target 5,31%
Spread / Average Target -12,3%
Spread / Lowest Target -27,5%
EPS Revisions
Managers
NameTitle
Akihiro Kobayashi President & Representative Director
Kazumasa Kobayashi Chairman
Noriaki Hirao Manager-Finance & Accounting
Haruo Tsuji Independent Outside Director
Satoshi Yamane Senior MD & Senior GM-Group Headquarters
Sector and Competitors
1st jan.Capitalization (M$)
KOBAYASHI PHARMACEUTICAL CO., LTD.11.65%7 738
THE PROCTER & GAMBLE COMPANY13.62%353 302
UNILEVER N.V.1.85%161 624
THE ESTÉE LAUDER COMPANIES INC.7.65%80 311
HINDUSTAN UNILEVER LIMITED13.29%69 790
COLGATE-PALMOLIVE COMPANY15.06%67 915